Current and emerging medications for overweight or obesity in people with comorbidities

Diabetes, Obesity and Metabolism

Volumn 17, Issue 11, 2015, Pages 1021-1032

  Fujioka, K ^a  

^a SCRIPPS CLINIC   (United States)

Author keywords

Comorbidities; Medication; Obese; Overweight; Pharmacological; Weight management

Indexed keywords

AMFEBUTAMONE PLUS NALTREXONE; AMFEBUTAMONE PLUS ZONISAMIDE; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BELORANIB; EXENDIN 4; FENFLURAMINE; LIRAGLUTIDE; LIXISENATIDE; LORCASERIN; PHENTERMINE; PHENTERMINE PLUS TOPIRAMATE; PLACEBO; TETRAHYDROLIPSTATIN; TOPIRAMATE; TRIACYLGLYCEROL LIPASE; AMFEBUTAMONE; ANTIOBESITY AGENT; CINNAMIC ACID DERIVATIVE; CKD732; CYCLOHEXANE DERIVATIVE; EPOXIDE; ISOXAZOLE DERIVATIVE; SESQUITERPENE; ZONISAMIDE;

ABDOMINAL PAIN; ACUTE PANCREATITIS; ATTENTION DISTURBANCE; BACKACHE; BODY MASS; BODY WEIGHT MANAGEMENT; CALORIC RESTRICTION; CHOLECYSTITIS; CHOLELITHIASIS; COGNITIVE DEFECT; COMORBIDITY; CONCENTRATION LOSS; CONFUSION; CONSTIPATION; COUGHING; DECREASED APPETITE; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DIET THERAPY; DIZZINESS; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; DYSLIPIDEMIA; DYSPEPSIA; EXERCISE; FATIGUE; FECES INCONTINENCE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; HEADACHE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INFUSION RELATED REACTION; INSOMNIA; LIFESTYLE MODIFICATION; LONG TERM CARE; MEMORY DISORDER; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PARESTHESIA; PHARMACEUTICAL CARE; PRACTICE GUIDELINE; REVIEW; RISK REDUCTION; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VOMITING; WEIGHT REDUCTION; XEROSTOMIA; DRUG EFFECTS; DYSLIPIDEMIAS; OVERWEIGHT; PREDIABETIC STATE;

ANTI-OBESITY AGENTS; BUPROPION; CINNAMATES; COMORBIDITY; CYCLOHEXANES; DIABETES MELLITUS; DYSLIPIDEMIAS; EPOXY COMPOUNDS; HUMANS; HYPERTENSION; ISOXAZOLES; OBESITY; OVERWEIGHT; PREDIABETIC STATE; SESQUITERPENES; WEIGHT LOSS;

EID: 84945459858     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12502     Document Type: Review

References (82)

1. World Health Organization. Obesity and overweight. Fact Sheet No 311. Reviewed January 2015. Available from URL: http://www.who.int/mediacentre/factsheets/fs311/en/. Accessed 22 June 2015.
2. Sharma AM, Kushner RF. A proposed clinical staging system for obesity. Int J Obes (Lond) 2009; 33: 289-295.
3. Guo F, Moellering DR, Garvey WT. The progression of cardiometabolic disease: validation of a new cardiometabolic disease staging system applicable to obesity. Obesity (Silver Spring) 2014; 22: 110-118.
4. Kramer CK, Zinman B, Retnakaran R. Are metabolically healthy overweight and obesity benign conditions? A systematic review and meta-analysis. Ann Intern Med 2013; 159: 758-769.
5. National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults - the evidence report. Obes Res 1998; 6 (Suppl 2): 51S-209.
6. Schelbert KB. Comorbidities of obesity. Prim Care 2009; 36: 271-285.
7. Naderpoor N, Shorakae S, Joham A, Boyle J, De Courten B, Teede HJ. Obesity and polycystic ovary syndrome. Minerva Endocrinol 2015; 40: 37-51.
8. Obesity Drugs Outcome Measures Dialogue Group, Ferguson C, David S, Divine L etal. Obesity Drugs Outcome Measures. 2012. Available from URL: http://publichealth.gwu.edu/pdf/obesitydrugmeasures.pdf. Accessed 26 May 2015.
9. Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995; 122: 481-486.
10. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. J Am Med Assoc 1999; 282: 1523-1529.
11. Saaristo TE, Barengo NC, Korpi-Hyövälti E etal. High prevalence of obesity, central obesity and abnormal glucose tolerance in the middle-aged Finnish population. BMC Public Health 2008; 8: 423.
12. Global Burden of Metabolic Risk Factors for Chronic Diseases Collaboration (BMI Mediated Effects), Lu Y, Hajifathalian K, Ezzati M etal. Metabolic mediators of the effects of body-mass index, overweight, and obesity on coronary heart disease and stroke: a pooled analysis of 97 prospective cohorts with 18 million participants. Lancet 2014; 383: 970-983.
13. de Wit L, Luppino F, van Straten A, Penninx B, Zitman F, Cuijpers P. Depression and obesity: a meta-analysis of community-based studies. Psychiatry Res 2010; 178: 230-235.
14. Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. J Am Med Assoc 2013; 309: 71-82.
15. Mechanick JI, Garber AJ, Handelsman Y, Garvey WT. American association of clinical endocrinologists' position statement on obesity and obesity medicine. Endocr Pract 2012; 18: 642-648.
16. American Medical Association. AMA adopts new policies on second day of voting at annual meeting. 2013. Available from URL: http://www.ama-assn.org/ama/pub/news/news/2013/2013-06-18-new-ama-policies-annual-meeting.page.Accessed 26 May 2015.
17. Council of the Obesity Society. Obesity as a disease: the obesity society council resolution. Obesity (Silver Spring) 2008; 16: 1151.
18. Apovian CM, Aronne LJ, Bessesen DH et al. Pharmacological management of obesity: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2015; 100: 342-362.
19. Jensen MD, Ryan DH, Apovian CM et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Obesity (Silver Spring) 2014; 22 (Suppl 2): S41-410.
20. Garber AJ, Abrahamson MJ, Barzilay JI et al. AACE/ACE comprehensive diabetes management algorithm 2015. Endocr Pract 2015; 21: 438-447.
21. Diabetes Prevention Program Research Group, Knowler WC, Fowler SE, Hamman RF etal. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009; 374: 1677-1686.
22. Lindström J, Peltonen M, Eriksson JG etal. Finnish Diabetes Prevention Study (DPS). Improved lifestyle and decreased diabetes risk over 13 years: long-term follow-up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia 2013; 56: 284-293.
23. Li G, Zhang P, Wang J etal. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes prevention study: a 20-year follow-up study. Lancet 2008; 371: 1783-1789.
24. Gregg EW, Chen H, Wagenknecht LE etal., Look AHEAD Research Group. Association of an intensive lifestyle intervention with remission of type 2 diabetes. J Am Med Assoc 2012; 308: 2489-2496.
25. Unick JL, Beavers D, Bond DS etal., Look AHEAD Research Group. The long-term effectiveness of a lifestyle intervention in severely obese individuals. Am J Med 2013; 126: 236-242, 242.e1-2.
26. Tsai AG, Wadden TA. Systematic review: an evaluation of major commercial weight loss programs in the United States. Ann Intern Med 2005; 142: 56-66.
27. Sjöström L. Review of the key results from the Swedish Obese Subjects (SOS) trial - a prospective controlled intervention study of bariatric surgery. J Intern Med 2013; 273: 219-234.
28. Gould JC. Bariatric surgery as a highly effective intervention for diabetes: news flash or preaching to the choir? Arch Surg 2012; 147: 700.
29. Grundy SM. Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. Nat Rev Drug Discov 2006; 5: 295-309.
30. Golay A. Metformin and body weight. Int J Obes (Lond) 2008; 32: 61-72.
31. Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. Br Med J 2012; 344: d7771.
32. Riser Taylor S, Harris KB. The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus. Pharmacotherapy 2013; 33: 984-999.
33. National Institutes of Health. The practical guide. Identification, evaluation, and treatment of overweight and obesity in adults. 2000. Available from URL: http://www.nhlbi.nih.gov/guidelines/obesity/prctgd_c.pdf. Accessed 26 May 2015.
34. Snow V, Barry P, Fitterman N etal. Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2005; 142: 525-531.
35. Food and Drug Administration. Drugs@FDA. 2015. Available from URL: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Search_Drug_Name. Accessed 26 May 2015.
36. European Medicines Agency. Medicines. 2015. Available from URL: http://www.ema.europa.eu/ema/. Accessed 26 May 2015.
37. Xenical Prescribing Information. 2013. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020766s033lbl.pdf. Accessed 26 May 2015.
38. Qsymia® Prescribing Information. 2014. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022580s004lbl.pdf.Accessed 26 May 2015.
39. BELVIQ® Prescribing Information. 2012. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022529lbl.pdf. Accessed 26 May 2015.
40. Contrave Prescribing Information. 2014. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/200063s000lbl.pdf. Accessed 26 May 2015.
41. Saxenda® Prescribing Information. 2015. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206321s001lbl.pdf. Accessed 26 May 2015.
42. Smith SR, Weissman NJ, Anderson CM etal., Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010; 363: 245-256.
43. Wadden TA, Hollander P, Klein S etal. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE maintenance randomized study. Int J Obes (Lond) 2013; 37: 1443-1451.
44. Niswender K, Pi-Sunyer X, Buse J etal. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes Obes Metab 2013; 15: 42-54.
45. ADIPEX-P® Prescribing Information. 2012. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/085128s065lbl.pdf. Accessed 26 May 2015.
46. Jordan J, Astrup A, Engeli S, Narkiewicz K, Day WW, Finer N. Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity. J Hypertens 2014; 32: 1178-1188.
47. Li Z, Maglione M, Tu W etal. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 2005; 142: 532-546.
48. Hendricks EJ, Greenway FL, Westman EC, Gupta AK. Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity. Obesity (Silver Spring) 2011; 19: 2351-2360.
49. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27: 155-161.
50. Thomas EL, Makwana A, Newbould R etal. Pragmatic study of orlistat 60mg on abdominal obesity. Eur J Clin Nutr 2011; 65: 1256-1262.
51. Bray GA, Hollander P, Klein S etal. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res 2003; 11: 722-733.
52. Allison DB, Gadde KM, Garvey WT etal. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring) 2012; 20: 330-342.
53. Gadde KM, Allison DB, Ryan DH etal. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377: 1341-1352.
54. Garvey WT, Ryan DH, Look M etal. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 2012; 95: 297-308.
55. Garvey WT, Ryan DH, Henry R etal. Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended-release. Diabetes Care 2014; 37: 912-921.
56. Winslow DH, Bowden CH, DiDonato KP, McCullough PA. A randomized, double-blind, placebo-controlled study of an oral, extended-release formulation of phentermine/topiramate for the treatment of obstructive sleep apnea in obese adults. Sleep 2012; 35: 1529-1539.
57. Fidler MC, Sanchez M, Raether B etal., BLOSSOM Clinical Trial Group. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab 2011; 96: 3067-3077.
58. O'Neil PM, Smith SR, Weissman NJ etal. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity 2012; 20: 1426-1436.
59. Centers for Disease Control and Prevention (CDC). Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services interim public health recommendations, November 1997. MMWR Morb Mortal Wkly Rep 1997; 46: 1061-1066.
60. Mysimba Summary of Product Characteristics. 2015. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003687/WC500185580.pdf. Accessed 26 May 2015.
61. Orexigen Therapeutics, Inc. Contrave (Naltrexone SR/Bupropion SR combination) Advisory Committee Briefing Document: NDA 200063. 2010. Available from URL: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM235672.pdf. Accessed 26 May 2015.
62. Smith SR, Fujioka K, Gupta AK etal. Combination therapy with naltrexone and bupropion for obesity reduces total and visceral adiposity. Diabetes Obes Metab 2013; 15: 863-866.
63. Hollander P, Gupta AK, Plodkowski R etal., COR-Diabetes Study Group. Effects of naltrexone sustained- release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care 2013; 36: 4022-4029.
64. Orexigen Therapeutics, Inc. Takeda pharmaceuticals and orexigen therapeutics announce termination of the cardiovascular uutcomes study (light study) of the obesity drug Contrave® (naltrexone HCl and bupropion HCl). 2015. Available from URL: http://ir.orexigen.com/phoenix.zhtml?c=207034&p=irol-newsArticle&ID=2046959. Accessed 26 May 2015.
65. Wadden TA, Foreyt JP, Foster GD etal. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring) 2011; 19: 110-120.
66. Greenway FL, Dunayevich E, Tollefson G etal., NB-201 Study Group. Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. J Clin Endocrinol Metab 2009; 94: 4898-4906.
67. Apovian CM, Aronne L, Rubino D etal. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring) 2013; 21: 935-943.
68. Astrup A, Carraro R, Finer N etal. NN8022-1807 Investigators. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond) 2012; 36: 843-854.
69. Saxenda® Summary of Product Characteristics. 2015. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003780/WC500185786.pdf. Accessed 22 June 2015.
70. van Can J, Sloth B, Jensen CB, Flint A, Blaak EE, Saris WH. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes (Lond) 2014; 38: 784-793.
71. Marso SP, Poulter NR, Nissen SE etal. Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. Am Heart J 2013; 166: 823-830.e5.
72. Fonseca VA, Devries JH, Henry RR, Donsmark M, Thomsen HF, Plutzky J. Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient-level pooled analysis of six randomized clinical trials. J Diabetes Complications 2014; 28: 399-405.
73. Novo Nordisk. Liraglutide 3.0mg for weight management briefing document. 2014. Available from URL: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/endocrinologicandmetabolicdrugsadvisorycommittee/ucm413318.pdf. Accessed 26 May 2015.
74. Bydureon Prescribing Information. 2015. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022200s019lbl.pdf. Accessed 26 May 2015.
75. Lixisenatide Summary of Product Characteristics. 2014. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002445/WC500140401.pdf. Accessed 25 March 2015.
76. Raccah D, Gourdy P, Sagnard L, Ceriello A. Lixisenatide as add-on to oral anti-diabetic therapy: an effective treatment for glycaemic control with body weight benefits in type 2 diabetes. Diabetes Metab Res Rev 2014; 30: 742-748.
77. Rosenstock J, Klaff LJ, Schwartz S etal. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes. Diabetes Care 2010; 33: 1173-1175.
78. Monami M, Nardini C, Mannucci E. Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2014; 16: 457-466.
79. Bays HE, Weinstein R, Law G, Canovatchel W. Canagliflozin: effects in overweight and obese subjects without diabetes mellitus. Obesity (Silver Spring) 2014; 22: 1042-1049.
80. Orexigen Therapeutics, Inc. Orexigen® Therapeutics phase 2b trial for Empatic™ meets primary efficacy endpoint demonstrating significantly greater weight loss versus comparators in obese patients. 2009. Available from URL: http://ir.orexigen.com/phoenix.zhtml%3Fc=207034%26p=irol-newsArticle%26ID=1336796%26highlight. Accessed 26 May 2015.
81. Hughes TE, Kim DD, Marjason J, Proietto J, Whitehead JP, Vath JE. Ascending dose-controlled trial of beloranib, a novel obesity treatment for safety, tolerability, and weight loss in obese women. Obesity (Silver Spring) 2013; 21: 1782-1788.
82. Kim DD, Krishnarajah J, Lillioja S etal. Efficacy and safety of beloranib for weight loss in obese adults: a randomized controlled trial. Diabetes Obes Metab 2015; 17: 566-572.